Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. (SYRE): 11 pipeline candidates · 1 upcoming catalyst · ~37 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
37.4 months
D/E 0.14 · 0% dilution
Lead: Phase 2
11 candidates
1 upcoming, next in ~196d
0 buys · 39 sells (180d)
A transparent, data-derived signal for Spyre Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$7.1B
Cash
$97.2M
Quarterly Burn
$57.4M
Runway
37.4 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (11 candidates)
| Drug | Phase |
|---|---|
| SPY001 | Phase 2 |
| spy001-001 | Phase 2 |
| SPY002 | Phase 2 |
| spy002-072 | Phase 2 |
| spy002-091 | Phase 2 |
| SPY003 | Phase 2 |
| spy003-207 | Phase 2 |
| SPY072 | Phase 2 |
| SPY120 | Phase 2 |
| SPY130 | Phase 2 |
Showing 10 of 11 candidates. Sign up for full pipeline.
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
196
Total value held
$4.16B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 11,781,024 | $594.2M |
| perceptive advisors llc | 7,566,450 | $381.7M |
| vanguard capital management llc | 6,114,802 | $308.4M |
| blackrock, inc. | 5,521,221 | $278.5M |
| rtw investments, lp | 4,171,996 | $210.4M |
| remedium capital partners, llc | 3,363,558 | $169.7M |
| janus henderson group plc | 3,312,328 | $167.2M |
| driehaus capital management llc | 2,790,785 | $140.8M |
| state street corp | 2,607,031 | $131.5M |
| commodore capital lp | 1,912,380 | $96.5M |
Showing top 10 of 196 institutional holders of Spyre Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Spyre Therapeutics, Inc.'s pipeline?
Spyre Therapeutics, Inc. (SYRE) has 11 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Spyre Therapeutics, Inc.'s lead drug candidate?
Spyre Therapeutics, Inc.'s most advanced tracked candidate is SPY001 (Phase 2) for Ulcerative Colitis.
What is Spyre Therapeutics, Inc.'s next catalyst?
Spyre Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: spy072" — expected December 31, 2026.
What is Spyre Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Spyre Therapeutics, Inc. has approximately 37.4 months of cash runway.
What is Spyre Therapeutics, Inc.'s market capitalization?
Spyre Therapeutics, Inc.'s market capitalization is approximately $7.1B.
Get the full picture on Spyre Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.